Tag: United Kingdom

cannabis joint lounge social use space consumption

UK Study Finds That Inhaled Cannabis Reduces Pain And Anxiety

When it comes to medical cannabis, inhaled consumption methods can be seen as controversial within certain medical and political circles. After all, so much effort has been spent encouraging people to not smoke tobacco cigarettes, and many people see the two products as being one and the same. However, tobacco and cannabis are not the same thing, and studies demonstrate that.

Many lawmakers around the globe seem to be hesitant to legalize medical cannabis in forms that involve inhalation, which is unfortunate. For many suffering patients, inhaling cannabis is the cheapest and easiest way to consume their medicine, and given that inhaled cannabis interacts with the human body quicker compared to ingested cannabis, many patients prefer it for one reason or another.

Suffering patients should be able to consume cannabis in any manner that helps them, including inhaling it. A recent study from the United Kingdom found that inhaled cannabis may help treat pain and anxiety. Below is more information about it via a news release from NORML:

London, United Kingdom: The sustained vaporization of THC-dominant cannabis flowers improves health-related quality of life measurements in patients suffering from chronic pain and anxiety-related disorders, according to observational data published in the journal Biomedicines.

A team of British and Spanish investigators assessed cannabis’ efficacy in a cohort of 451 British patients authorized to consume cannabis flowers for treatment-resistant pain and/or anxiety. Patients in the study were all enrolled with Project Twenty21, “the first U.K. multi-center registry seeking to develop a body of real-world evidence to inform on the effectiveness and safety of medical cannabis.” All of the study’s participants had failed to respond to at least two prescription treatment options prior to obtaining an authorization for medical cannabis. All participants vaporized cannabis flowers for a period of at least three months.

Researchers reported that cannabis inhalation was associated with sustained (6+ months) improvements in both patient populations and that side effects were “minimal.” Investigators reported more significant improvements among those diagnosed with treatment-resistant anxiety.

“Our results indicate that controlled inhalation of pharmaceutical grade, THC-predominant cannabis flos [flowers] is associated with a significant improvement in patient-reported pain scores, mood, anxiety, sleep disturbances and overall HRQoL [health-related quality of life] in a treatment-resistant clinical population,” authors concluded.

Numerous surveys indicate that patients most frequently self-report using cannabis to mitigate symptoms of pain and anxiety.

Full text of the study, “Controlled inhalation of THC-predominant cannabis flos (flowers for inhalation) improves health-related quality of life and symptoms of pain and anxiety in eligible UK patients,” appears in Biomedicines.

United Kingdom

running jogging

UK Study Finds Cannabis Consumption Is Not Linked To Changes In Motivation

Historically, cannabis consumers have been portrayed by cannabis opponents as lazy ‘do nothings’ that sit on couches all day eating potato chips. Those stereotypes have also been perpetuated in mainstream media.

Unfortunately for cannabis opponents, there are numerous examples of people in peak physical condition that consume cannabis every single day, as demonstrated by the growing number of professional athletes that are coming out of the cannabis closet.

To be fair, there are certainly cannabis consumers that lack motivation, however, it’s not because of the cannabis. Some people are just lazy. That is reflected in the results of a recent study out of the United Kingdom. Below is more information about it via a news release from NORML:

London, United Kingdom: Neither adults nor young people who consume cannabis exhibit symptoms of so-called ‘a-motivational syndrome,’ according to case control data published in The International Journal of Neuropsychopharmacology.

British researchers assessed apathy, anhedonia (an inability to feel pleasure), and effort-based decision making in a cohort of late-adolescent and young adult cannabis consumers. Their performance was compared to that of age-matched controls (non-cannabis consumers).

Researchers identified no significant differences between the two groups.

“Cannabis use has historically been linked with a-motivation, which is reflected in prevalent, pejorative ‘lazy stoner’ stereotypes. In this study, we counter this cliché by showing that a relatively large group of adult and adolescent cannabis users and controls did not differ on several measures of reward and motivation,” they concluded. “Specifically, people who used cannabis on average four days per week did not report greater apathy or anhedonia, reduced willingness to expend effort for reward, or reduced reward wanting or liking compared to people who did not use cannabis. … Our results add to the growing body of evidence suggesting that non-acute cannabis use is not linked with amotivation, which may help to reduce stigma experienced by people who use cannabis.”

The investigators’ findings are consistent with those of other recent studies refuting long standing claims that those with a history of marijuana use typically lack motivation.

Full text of the study, “Anhedonia, apathy, pleasure, and effort-based decision-making in adult and adolescent cannabis users and controls,” appears in The International Journal of Neuropsychopharmacology.

United Kingdom

united kingdom flag

Liz Truss Makes It Clear Where She Stands On Cannabis Policy

Cannabis reform is one of the most popular political issues on earth right now, particularly in North America and Europe. At a time when it seems like people rarely agree on anything, cannabis is one area of public policy where support is strong and cuts across party lines. Unfortunately, that support does not appear to extend to the office of the United Kingdom’s Prime Minister, with the UK announcing this week that it is officially blocking a cannabis reform measure that was previously passed by lawmakers in Bermuda earlier this year.

Liz Truss took over as Prime Minister in the United Kingdom this week, and shortly after taking office her government announced the official blockage of the cannabis reform measure in Bermuda. Cannabis policy observers around the globe were hopeful that upon taking office that Truss would pursue a new era for cannabis policy in the UK, however, being that she is blocking cannabis reform elsewhere it’s very clear where she stands when it comes to cannabis policy.

Actions Speak Louder Than Words

Truss, like many politicians, has a checkered past when it comes to cannabis policy. Leading up to the Prime Minister transition in the UK, Truss was criticized by opponents for her previously expressed support for cannabis reform. Apparently, a leaflet edited by Liz Truss when she was a leading Lib Dem at Oxford University surfaced in which it was asked if cannabis should be legalized, a position that Truss reportedly supported back then.

The newly installed Prime Minister has been criticized by both cannabis supporters and opponents for ‘flip flopping’ on the issue, with many asking the logical question, ‘where does Liz Truss really stand when it comes to cannabis reform?’ Unfortunately, we found out the answer to that question this week, and it wasn’t a favorable answer.

Politicians of all backgrounds and at all levels will often tell voters what they think they want to hear. It is no secret that many people who seek public office will say whatever it takes to get elected, even if what they are saying to one audience completely contradicts what they are telling a different audience. That is politics as usual, and the real measure of a politician on any given issue is what actions they take (or do not take) once they get into a position to actually do something regarding the particular issue.

Colonization on Full Display

In order for cannabis reform to move forward in Bermuda, the measure has to receive blessing from the United Kingdom in the form of ‘royal assent.’ It’s a concept that is born out of the United Kingdom’s (Britain) colonization of Bermuda centuries ago. Bermuda remains the oldest British colony in existence, which in itself needs to be addressed.

Lawmakers in Bermuda deserve to set their own laws. No one in the United Kingdom should be able to prevent a law from taking effect in Bermuda, whether it’s related to cannabis or anything else. Citizens in Bermuda elect their own representatives, and those representatives should be able to carry out ‘the people’s work’ without interference from countries across the Atlantic Ocean.

Fortunately, it sounds like lawmakers in Bermuda are going to proceed forward with their plans despite the opposition by Liz Truss’ government. It sets up a constitutional showdown between the UK and Bermuda, and in the first week of Truss’ tenure as Prime Minister no less. With all of the problems out there in the world, it’s a shame that any time and effort is being spent on preventing the will of Bermuda’s citizens. The only ‘benefit’ to the saga is that it makes clear where Liz Truss stands on cannabis policy, for better or worse.

bermuda, liz truss, United Kingdom

pain menopause menstrual cycle urological cancer

Prior Cannabis Use Inversely Associated With Urological Cancers

Urological cancers can occur in both men and women and are caused by abnormal cell growths in the organs of the urinary tract and the male reproductive tract.

The specific types of urological cancers can affect the kidneys, ureter, bladder, urethra, prostate, and/or testicles. The most common type of urologic cancer is bladder cancer.

Various things can contribute to the development of urological cancers, including genetics and environmental factors, with tobacco use being a notable contributing factor.

Common treatments include surgery, radiation, chemotherapy, and in some cases immunotherapy. Past cannabis use is associated with a lower risk of urological cancers according to a new study. Below is more information about it via a news release from NORML:

London, United Kingdom: Women with a past history of cannabis use are at lower risk of suffering from certain types of urological cancers, according to population-based data published in the journal Cancer Medicine.

An international team of researchers from China, France, and the United Kingdom assessed the relationship between cannabis use and cancer risk in a cohort of more than 151,000 subjects.

Investigators reported, “Previous use of cannabis was a significant protective factor” in women against renal cell carcinoma (RCC) and bladder cancer (BCa). They further reported that “previous cannabis use was a significant protective factor for PCa (prostate cancer) in men with a history of tobacco smoking.” A history of cannabis use had a null effect on rates of testicular cancer.

Authors concluded: “In the current study, we investigated the association between the use of cannabis and the risk of urological cancers. We observed that: (1) previous use of cannabis was a significant inverse association with both RCC and PCa; (2) cannabis use was associated with the lower risk of BCa in the point estimates; (3) the protective effect of cannabis on RCC and BCa was significant for females but not for males; (4) cannabis use had a causal effect on lower incidence of RCC.”

Prior studies have similarly identified an inverse association between a past history of cannabis use and the development of certain types of cancers, including bladder cancer, liver cancer, and head and neck cancers.

Full text of the study, “Association between cannabis use with urological cancers: A population-based cohort study and mendelian randomization study in the UK biobank,” appears in Cancer Medicine.

cancer, United Kingdom

london bridge england united kingdom britain

UK’s Top Contender For Prime Minister Criticized For U-Turn On Cannabis Reform

In an increasingly bitter and close race, Tory rival for the top political job, Rishi Sunak has criticized Liz Truss for her flip-flop on cannabis reform

The current political battle in the UK to replace Boris Johnson has gotten increasingly nasty if not out of touch with the issues that most people are now facing. The top two rivals for the Prime Minister’s office, have been slugging away at each other’s policies for weeks now.

Given this, it was inevitable that the issue of cannabis reform would surface, in some form.

Now Rishi Sunak, dubbed “Dishy Rishi” by his detractors, who would become not only the first non-white Prime Minister but the first practicing Hindu to hold the office, has gone there. Specifically, he has attacked Liz Truss, his opponent, for once supporting cannabis reform – when she was a student at Oxford and the one-time president of the Oxford Liberal Democrats.

Interestingly, Sunak, who also spent time in California while attending Stanford University to obtain an MBA degree, is not taking a stand on cannabis reform, even of the medical kind. His criticism is that Truss is a politician who will flip flop to gain political advantage and holds no fixed beliefs. She currently opposes cannabis reform as a member of the Tory party.

It is the kind of campaign not seen (yet) in the United States or Germany – two countries where the issue of federal cannabis reform is now looming. It is also a sign of how far even medical cannabis reform still has to go in the UK – forget full legalization.

Where Cannabis Reform Now Stands in Britain

The UK is now suffering from high inflation, post-Brexit woes, and a political discussion that has been warped beyond recognition because of the same. As literally millions of Britons are suffering from energy costs that have increased dramatically this year plus food and medicine shortages, the Tory leadership battle has focussed on esoteric issues that have little to do with the major problems now faced by the majority of the country.

In the meantime, the government is at a literal standstill under the lame duck tenancy of Boris Johnson, who was forced out by members of his own party after one too many scandals earlier this summer.

The issue of cannabis reform is, as a result, unlikely to become a political force on a national level in this kind of environment. Indeed, it has stagnated all over the country, even in places like the Channel Islands where local support had gelled for proceeding.

It is unlikely that the UK will be able to hold out forever, no matter who wins the current leadership contest. Indeed, it will be a potent political issue in the next national election, due to be held in the next several years.

Until then, however, look for the same old, tired excuses for failing to enact more comprehensive policies from the Tory party as cannabis patients continue to suffer and people are convicted of criminal charges even for small amounts of cannabis. There are currently an estimated 17,000 “legal” cannabis patients in Britain.

United Kingdom

london bridge england united kingdom britain

UK’s Lack Of Comprehensive Cannabis Policy Criticized

A Report Launched by UK Minister for Science, Research and Innovation criticizes a lack of coordinated policy on “cannabinoid innovation”

The UK government is criticizing itself in a new report to be launched by the Minister of Science, Research, and Innovation – namely calling on the government to turbocharge cannabis innovation rather than continuing to take a disinterested approach to the sector.

It also explicitly criticizes the approach so far.

According to the report, “It is not sustainable or acceptable for the [UK] Government to continue to take an uncoordinated, disinterested or laissez-faire attitude to the sector as a whole, as it has done since the cannabis sector’s 2018 inception.”

The 24-page document quotes leading industry players, academics, patients, consumers, and investors.

Beyond being critical of the progress so far, however, the report also lists twenty ways in which the UK can create a best-in-class cannabis sector.

Commissioned by the Centre for Medicinal Cannabis and the Association for the Cannabinoid Industry, the report was authored by Professor Christopher Hodges, a well-known regulatory expert, and thought leaders. The work will also be launched with a speech from George Freeman, a member of parliament and the minister of the agency which is ultimately responsible for the report.

It is, as a result, the first-ever ministerial address about the cannabis sector in the UK.

Evolving By Accident

According to the report, the market has “evolved by accident, without coordinated government action or a coherent strategy to steward it to maturity.” They further offer some interesting findings including that 1 in 7 Britons use cannabis for medical if not health reasons and that 64% of the population believes that scientific study of cannabinoids should be supported by the government.

A New Regulatory Schemata

Arguing that the framework established by the report would create a global advantage for post-Brexit Britain, Professor Hodges, an Emeritus Professor of Justice Systems at the Centre for Socio-Legal Studies at Oxford, also calls for specific changes that could be made quickly and easily.

These include allowing GPs to prescribe medical cannabis rather than specialists, modernizing the Proceeds of Crime Act, creating a national patient registry, and updating the rules about farming hemp. The report also calls for the creation of a “stewarding authority” to implement the suggested reforms as well as govern and guide the sector forward.

Through these suggestions, the report authors hope to create jobs, attract more investment, and secure both political support and public recognition.

United Kingdom

london england united kingdom big ben

London Mayor Launches Commission To Examine Cannabis Policy

Cannabis reform is sweeping the European continent, with at least one country now a legal jurisdiction for adult use. Late last year Malta became the first country in Europe to pass an adult-use legalization measure.

Italy was on track to possibly legalize cannabis this year after activists gathered and submitted over 630,000 signatures in an attempt to put legalization in front of voters. Unfortunately, even though the effort proved to have gathered enough valid signatures Italy’s government stopped the effort in its tracks, claiming that it was unconstitutional to let it proceed.

Cannabis legalization pilot programs are starting to spread across Europe. Copenhagen already has a program underway and the pilot program is set to expand across Denmark as more jurisdictions sign up. Switzerland is launching its first pilot program site in Basel this summer, and hopefully by 2023, the Netherlands will do the same.

Germany’s governing coalition previously announced plans to legalize cannabis in the near future, and last week Germany’s Health Minister announced that the timeline for legalization would be sped up with legalization possibly coming as soon as this summer.

In the midst of all of the momentum for cannabis reform on the continent one country that has moved almost as slow as any other nation is the United Kingdom. The UK’s medical cannabis program is extremely limited and has only helped a minor fraction of the number of suffering patients that exist in the UK. Recreational cannabis possession and use remain prohibited.

London’s Mayor, Sadiq Khan, announced this week that a commission will be launched to explore, among other things, cannabis policy reform. Per The Guardian:

Sadiq Khan has announced a commission to examine the effectiveness of the UK’s drug laws, with a particular focus on those governing cannabis.

The London drugs commission, to be chaired by Lord Charlie Falconer QC, a former lord chancellor and justice secretary, was one of Khan’s manifesto pledges in his re-election bid last year.

The mayor of London’s office said a panel of independent experts in criminal justice, public health, politics, community relations and academia will be assembled to consider evidence from around the world on the outcomes of various drug policies.

The announcement was made while Khan was in Los Angeles where he toured a cannabis cultivation facility. The announcement of the commission yielded swift pushback from the Home Secretary of the United Kingdom Priti Patel. Per The Times:

The home secretary has criticised the mayor of London after he set up a commission to consider the decriminalisation of cannabis.

Priti Patel told Sadiq Kahn that he “has no powers to legalise drugs”.

“Sadiq Khan’s time would be better spent focusing on knife and drug crime in London. The mayor has no powers to legalise drugs. They ruin communities, tear apart families and destroy lives,” Patel said in a tweet.

For starters, the War on Drugs ruins communities, tears apart families, and destroys lives. That is a fact. It is also a fact that the War on Drugs has failed, both in the United Kingdom and beyond. Patel’s tweet obviously disregards those facts.

Secondly, as I understand it, what Khan has proposed is essentially a fact-finding commission, not a commission that will actually seek to change policies. I suppose that it could evolve to a point where that is being pursued, however, that does not appear to be the case right now.

What does appear to be the case, at least in my opinion, is that Patel and other like-minded officials are probably scared of what the commission will potentially find and publish. It’s much easier for Patel and others to peddle reefer madness rhetoric without the existence of a commission like the one that Khan is launching.

england, london, United Kingdom

CBD oil

UK Government Fund Invests In Cannabis Company

During the pandemic, the United Kingdom set up a fund called the ‘British Business Bank’s Future Fund.’ The aim of the taxpayer-backed fund was to ‘support innovative companies that might have struggled to secure money during the pandemic.’

The fund recently announced another round of applicant approvals, and among the winners of the government investments was a cannabis company that specializes in making hemp-derived oil. Per excerpts from The Guardian:

The UK government has become a shareholder in a cannabis oil company, a yoghurt bar business, a London-based craft brewery and a maker of land, underwater and air drones that “take inspiration from the clever tricks that animals use to move”.

The latest round of investments include Grass & Co, founded by brothers Ben and Tom Grass in 2019, which makes cannabidiol (CBD) products using chemicals found in hemp, which are stocked in stores including Selfridges and Boots.

According to coverage by The Guardian, the fund has shelled out over £1.4 billion to a total of 1,190 companies so far, with 335 of those companies converting government loans into government equity stakes after finding private investments to match the government’s money.

The investment into the CBD oil company is bittersweet, in that it’s obviously great news for the recipient and great to see the United Kingdom recognize the economic potential of the merging cannabis industry, however, to some degree it highlights the deficiencies of the United Kingdom’s medical cannabis program.

As we previously reported, out of an estimated 1.4 million suffering patients, only thousands of patients have been prescribed a cannabis product by the United Kingdom directly, or indirectly via a private medical practitioner.

Patients deserve unfettered safe access to all forms of effective medical cannabis, which is unfortunately not the case in the United Kingdom.


United Kingdom

london bridge england united kingdom britain

How Many UK Patients Are Being Privately Prescribed Cannabis?

The United Kingdom is a fairly rough place when it comes to safe access to medical cannabis. The country’s medical cannabis program is notoriously restrictive, leaving suffering patients with little to no options depending on the situation.

For starters, the number of medical products that are considered to be legal in the United Kingdom is very low. Raw flower is not available to patients, and patients are not permitted to cultivate their own cannabis.

The National Health Service only allows cannabis-based products. Below is the definition of what that involves, via the National Health Service’s website:

There are three broad requirements that a product should satisfy:

  • The product is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative
  • It is produced for medicinal use in humans; and
  • It is a product that is regulated as a medicinal product, or an ingredient of a medicinal product.

The definition is necessarily broad to take account of the range of preparations which are cannabis-based that have been used for therapeutic purposes and to ensure that raw products/ingredients and intermediate products are captured.This is essential to ensure that where there is a clinical need, a patient will be able to access appropriate cannabis-based medicines and/or products can be made to meet any prescription.

Patients can get a prescription for a cannabis-based product through the National Health Service (NHS), however, as of last summer only 3 prescriptions had reportedly been issued by NHS.

Filling the void left by the NHS is private prescriptions. The prescriptions can only be issued by clinicians listed on the Specialist Register of the General Medical Council, and even then, the products eligible for a prescription are limited.

According to a new report from Prohibition Partners, private prescriptions have risen in the last two years. Below is an excerpt from their report:

Based on Prohibition Partners’ calculations, which conservatively assume all quarters in 2021 are equal, the annual number of products for last year amounted to 23,466 – a 425% increase on 2020. Things are moving more quickly elsewhere in the UK. On the island of Jersey, with a population of just over 100,000 inhabitants, more than 2,000 prescriptions were filled from January 2019 up to late 2021.

To put the figures into perspective, Prohibition Partners estimates that there are as many as 1.4 million patients in the United Kingdom that would purchase medical cannabis products if they were able to.

With that in mind, the uptick in private prescriptions in the UK is welcomed news, however, the UK’s medical cannabis program still has a long way to go when it comes to improving safe access for suffering patients.

In addition to expanding the type of products that patients can acquire, such as raw flower, patients also need to be able to cultivate their own medicine if they choose to do so, among other much-needed improvements.

United Kingdom

CBD oil

UK Becomes First Country To Regulate CBD Products As Food

The Food Safety Commission issued an official list of legal CBD products that can be sold in the UK and Wales

There is not a lot to cheer about in the British cannabis industry, generally. So far, the medical discussion has repeatedly stalled.

However, there is a ray of light on the horizon for CBD products.

Last week the British FSA issued a list of officially recognized products that are legally allowed to be sold. There are about 3,500 products on the list. Any products that are not on the list will be now considered illegal products and vendors who sell them will be open to prosecution. However, this is not a definitive list, and other products can be added.

About 900 applications were submitted before the government deadline, of which 71 progressed. This has now resulted in said applications being used in 3,500 products. 680 applications were rejected, and 42 applications were withdrawn from companies that no longer wished to move forward with the process.

The list covers products that can be sold in England and Wales. Scotland will have its own regulatory oversight and process. Only Northern Ireland has refrained from moving forward with even CBD reform as it remains under the jurisdiction of the EU – which has yet to approve any CBD-based food or supplements.

A Boom for British CBD

The move is likely to create a highly entrepreneurial environment for at least part of the cannabis industry. Unlike the US, where CBD has been federally legal since the passage of the 2018 Farm Bill, the British will have a formal list to guide both consumers and investors.

This in turn is likely to create Europe’s first viable, commercial CBD market, and further one that may well influence decision-makers in the EU.

Annual sales of British CBD products hit about $898 million in sales in 2021, making the UK the world’s second-largest CBD market outside of the US.

The UK legalized CBD in 2018, but the market has been slowed down both by Covid and by the approvals process at the FSA.

Now that the FSA has released a formal list, however, legal sales can proceed unfettered.

CBD is perhaps the second-best known cannabinoid after THC. It has no psychoactive effects, but has been shown to have anti-inflammatory and other medical impacts. It is most currently viewed as a wellness product, although there are some medicines that are made only from CBD.

Let the games if not sales begin!

United Kingdom

cannabis flower bud nug

UK Approves First ‘Pure Cannabis’ Trial For Chronic Pain

When it comes to medical cannabis programs around the globe, the United Kingdom ranks near the bottom of any list. A medical program is only as good as the number of suffering patients that it helps provide safe access to, and as of last summer, the number of patients helped in the United Kingdom was dismal.

Per a report by Vice from last summer, “there have been just three NHS prescriptions of cannabis oil. A private market is growing – with roughly 6,000 prescriptions issued – but many struggle to pay the expensive fees each month.”

The fact of the matter is that the United Kingdom’s medical program is extremely restrictive and essentially set up to give a virtual monopoly to pharmaceutical cannabis. The current setup is not good for patients being that so few want to use pharmaceutical cannabis products, and it’s also not good for the makers of pharmaceutical cannabis products because their market base is extremely small. No one is ‘winning’ in the current medical cannabis model in the UK.

Lawmakers and regulators in the UK have made it clear that they want to conduct more research before expanding the medical cannabis program, and fortunately more research appears to be on the way, and involving raw cannabis no less. Per The Times:

Thousands of Britons will be given cannabis for pain relief under a proposed clinical trial that could pave the way for millions to get the drug on the NHS.

Medical regulators have approved the UK’s first trial of pure cannabis for people with chronic pain caused by conditions including arthritis, The Times can reveal.

Some 5,000 adults will take vaporised cannabis daily for at least a year through inhalers that dispense cartridges containing a measured dose of “whole flower” unprocessed marijuana.

This is a small, yet significant step that will hopefully yield meaningful movement for improving the UK’s medical cannabis program. Studies that involve ‘whole flower’ are often more insightful compared to studies that only use pharmaceutical cannabis products being that most patients consume raw flower as part of their medical cannabis regimens.

The study is expected to launch ‘later this year’ and as pointed out by The Times, the study itself will go for at least one year. That means that at the earliest some, but perhaps not all, of the study’s results will be released in late 2023. You then have to assume that lawmakers and regulators will ponder the results for some amount of time before taking action, and it’s anyone’s guess how long that process will take.

At some point, after the study is finished and after the results are released and after the National Institute for Health and Care Excellence offers up its recommendation, the results of this study could lead to as many as 15 million patients in the United Kingdom finally being able to vaporize cannabis flower. It’s going to be a long process, however, it’s better than nothing I suppose.

United Kingdom

television tv

Mixing Media With Cannabis In The UK

Channel 4, a British TV company, has just invested in Cannaray, a Canadian-British cannabis company. What is next for the UK market if not cannabis media?

In a move that certainly is rather surprising, given the fact that media companies so far have largely stayed clear of the “biz,” Channel 4 in the UK has now invested in a British-based, Canadian cannabis company looking to expand to Europe.

Channel 4 is a bit of an anomaly in the UK. Unlike the BBC (or the Beeb) it is a non-government-run, but free-to-air, public service television network. Headquartered in Leeds, it has hubs in Glasgow and Bristol. It was founded in 1982 and also has a film unit.

It makes its money in ways familiar to American viewers – namely via advertisements but also via sponsored programs.

The fact that their venture unit has now invested in a cannabis company is certainly going to make waves, especially considering the strange legal territory even CBD falls under.

Canna TV?

The first and most interesting impact this partnership is likely to have is in the field of CBD advertising, which, given the forward motion of the Food Safety Authority on cannabidiol, is likely also to create, for the first time, a venue for CBD product advertising if not program sponsorship in the UK. Given the hunger in the market for any kind of PR and marketing, this is likely to be a profitable venture for at least Channel 4 itself if not the budding British CBD biz beyond this.

Beyond that, however, given the impact of digital television and social media outtakes, this could well become a model for cannabis advertising and media sponsorship across Europe.

Canna Cooking Shows?

Given that the top shows by audience demographics since the station began broadcasting are episodes of The Great British Bake-off, it should not surprise anyone if cannabis becomes a regular ingredient in this programming mix. This is especially true given the station’s predilection for importing programming from North America.

What About Other Cannabis Products?

Europe and the UK have different advertising policies about medical products, which for now, THC certainly falls under. However, given the fact that medical cannabis, generally, has many interesting intersections with popular culture, it is clear that there is a possibility for some good old cannabis education that reaches the masses about other cannabinoids, including THC.

Stay tuned.

United Kingdom

  • 1
  • 2
International Cannabis Business Conference



© International Cannabis Chronicle. All rights reserved. Site developed and hosted by Rogue Web Works.